Table 1. Patient characteristics at diagnosis.
| Bevacizumab group (n=64) | Non-bevacizumab Group (n=99) | P-value | |
|---|---|---|---|
| Age (years), mean (SD) | 66.1 (14.2) | 63.7 (14.4) | 0.33a |
| Male gender, n (%) | 27 (47) | 58 (62) | 0.090b |
| Ethnicity, n (%) | 0.78c | ||
| Caucasian | 10 (18) | 11 (15) | |
| Hispanic | 27 (49) | 44 (60) | |
| African ancestry | 15 (27) | 15 (21) | |
| Other | 1 (2) | 3 (4) | |
| Causes of NVG, n (%) | 0.41c | ||
| DM type 2 | 29 (46) | 39 (42) | |
| CRVO | 16 (25) | 37 (39) | |
| DM type 1 | 5 (8) | 6 (6) | |
| OIS | 3 (5) | 3 (3) | |
| Other | 10 (16) | 9 (10) | |
| Visual acuity | |||
| Median (range) | 3/200 (20/40-LP) | CF (20/25-NLP) | 0.38d |
| HM or better acuity, n (%) | 55 (86) | 79 (80) | 0.40b |
| IOP, mean (SD) | 40.8 (11.5) | 43.1 (13.0) | 0.25a |
| Glaucoma meds, mean (SD) | 0.9 (1.4) | 1.4 (1.5) | 0.027a |
| Prior ocular surgeries, n (%) | |||
| Cataract extraction | 35 (56) | 18 (18) | <0.001b |
| Trabeculectomy/GDI | 1 (2) | 3 (3) | 1.00b |
| PRP | 22 (34) | 28 (28) | 0.49b |
| PPV | 15 (23) | 10 (10) | 0.026b |
Abbreviations: CF, count fingers; CRVO, central retinal vein occlusion; DM, diabetes mellitus; GDI, glaucoma drainage implant; HM, hand motion; IOP, intraocular pressure; LP, light perception; Meds, medications; OIS, ocular ischemic syndrome; PPV, pars plana vitrectomy; PRP, panretinal photocoagulation.
a
Two-sample t-test.
b
Fisher exact test.
c
χ2 test.
d
Two-sample Wilcoxon test.